0
Editorials |

Who Is (Still) Getting HIT?

Theodore E. Warkentin, MD; John W. Eikelboom, MBBS, MSc
Author and Funding Information

Affiliations: Hamilton, ON, Canada ,  Dr. Warkentin is Professor, Departments of Pathology and Molecular Medicine, and Medicine, McMaster University, Hamilton, ON, Canada. He is also Associate Head, Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, and is a hematologist at the Hamilton Health Sciences (Hamilton General Site). Dr. Eikelboom is Associate Professor, Department of Medicine, McMaster University, Hamilton, ON, Canada, and is a hematologist at the Hamilton Health Sciences (Hamilton General Site).

Correspondence to: Theodore E. Warkentin, MD, Room 1–180A, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences (Hamilton General Site), 237 Barton St E, Hamilton, ON L8L2X2, Canada; e-mail: twarken@mcmaster.ca



Chest. 2007;131(6):1620-1622. doi:10.1378/chest.07-0425
Text Size: A A A
Published online

Extract

Heparin-induced thrombocytopenia (HIT) is an important adverse effect of heparin therapy that is caused by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies. Among the reasons for its importance are its paradoxical association with thrombosis (the very complication that heparin was intended to prevent) and its relatively common occurrence.1 There are at least four factors that influence the risk of HIT, as follows (Table 1 )5: duration of heparin therapy; type of heparin used; type of patient population; and patient sex.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543